tavaborole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4877 | 174671-46-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of tavaborole is inhibition of fungal protein synthesis. Tavaborole inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).Tavaborole has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 7, 2014 | FDA | ANACOR PHARMS INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AE24 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
| FDA CS | M0002832 | Boron Compounds |
| FDA MoA | N0000000150 | Protein Synthesis Inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| FDA EPC | N0000191279 | Oxaborole Antifungal |
| CHEBI has role | CHEBI:35718 | antifungal agents |
| CHEBI has role | CHEBI:48001 | protein synthesis inhibitors |
| CHEBI has role | CHEBI:77953 | EC 6.1.1.4 inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Onychomycosis due to Trichophyton mentagrophytes | indication | 23549005 | |
| Onychomycosis due to Trichophyton rubrum | indication | 56922006 | |
| Onychomycosis due to dermatophyte | indication | 402134005 | |
| Onychomycosis of toenails | indication | 403059006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.49 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 2 | Enzyme | Ki | 6.33 | CHEMBL | |||||
| Carbonic anhydrase 1 | Enzyme | Ki | 5.70 | CHEMBL | |||||
| Leucine-tRNA ligase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 7.14 | CHEMBL | |||||
| Carbonic anhydrase 2 | Enzyme | Ki | 7.05 | CHEMBL | |||||
| Leucine--tRNA ligase, cytoplasmic | Enzyme | Ki | 5.73 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D10169 | KEGG_DRUG |
| 4033648 | VUID |
| N0000191084 | NUI |
| 4033648 | VANDF |
| CHEBI:77942 | CHEBI |
| CHEMBL443052 | ChEMBL_ID |
| C512998 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB09041 | DRUGBANK_ID |
| 1543173 | RXNORM |
| 222423 | MMSL |
| 30392 | MMSL |
| 340008 | MMSL |
| 015655 | NDDF |
| 716264009 | SNOMEDCT_US |
| 763516005 | SNOMEDCT_US |
| C3642427 | UMLSCUI |
| 9425 | INN_ID |
| 11499245 | PUBCHEM_CID |
| K124A4EUQ3 | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0157 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 25 sections |
| Kerydin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10337-905 | SOLUTION | 43.50 mg | TOPICAL | NDA | 26 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21922-020 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 24 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21922-020 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 24 sections |
| TAVABOROLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1397 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 26 sections |
| tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-690 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 28 sections |
| tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-690 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 28 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62332-467 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 23 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62332-467 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 23 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8704 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 25 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8704 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 25 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8704 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 25 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-958 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 22 sections |
| TAVABOROLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-686 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 24 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69238-1657 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 24 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69238-1657 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 24 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1826 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 1 sections |
| TAVABOROLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71589-010 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 22 sections |
| Tavaborole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72578-102 | SOLUTION | 43.50 mg | TOPICAL | ANDA | 24 sections |